✓ No loaded language, vague sourcing, or framing detected.
An FDA advisory panel has recommended the approval of Moderna's mRNA flu vaccine, mFlusiva, for older adults. The unanimous vote of 9-0 indicates that the panel believes the benefits of the vaccine outweigh its risks for individuals aged 50 and above.
Our neutral summary
An FDA advisory panel has recommended the approval of Moderna's mRNA flu vaccine, mFlusiva, for older adults. The unanimous vote of 9-0 indicates that the panel believes the benefits of the vaccine outweigh its risks for individuals aged 50 and above.
The reporting belongs to The Hill; we don't reproduce it.
No note attached
on this article.
FDA panel recommends mRNA flu vaccine for older adults
FDA Advisory Panel Recommends Approval of Moderna's mRNA Flu Vaccine for Older Adults